[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

HK1045646A1 - Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof - Google Patents

Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof

Info

Publication number
HK1045646A1
HK1045646A1 HK02105870.2A HK02105870A HK1045646A1 HK 1045646 A1 HK1045646 A1 HK 1045646A1 HK 02105870 A HK02105870 A HK 02105870A HK 1045646 A1 HK1045646 A1 HK 1045646A1
Authority
HK
Hong Kong
Prior art keywords
methods
preparation
active agents
pharmacologically active
protein stabilized
Prior art date
Application number
HK02105870.2A
Other languages
Chinese (zh)
Inventor
P Desai Neil
Tao Chunlin
Yang Andrew
Louie Leslie
Yao Zhiwen
Soon-Shiong Patrick
Magdassi Shlomo
Original Assignee
Abraxis Bioscience Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/316,642 external-priority patent/US6749868B1/en
Application filed by Abraxis Bioscience Llc filed Critical Abraxis Bioscience Llc
Publication of HK1045646A1 publication Critical patent/HK1045646A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5169—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
HK02105870.2A 1999-05-21 2002-08-12 Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof HK1045646A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/316,642 US6749868B1 (en) 1993-02-22 1999-05-21 Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
PCT/US2000/013954 WO2000071079A2 (en) 1999-05-21 2000-05-19 Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof

Publications (1)

Publication Number Publication Date
HK1045646A1 true HK1045646A1 (en) 2002-12-06

Family

ID=23229970

Family Applications (1)

Application Number Title Priority Date Filing Date
HK02105870.2A HK1045646A1 (en) 1999-05-21 2002-08-12 Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof

Country Status (5)

Country Link
EP (1) EP1178786A4 (en)
AU (3) AU784416B2 (en)
CA (2) CA2371912C (en)
HK (1) HK1045646A1 (en)
WO (1) WO2000071079A2 (en)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8853260B2 (en) 1997-06-27 2014-10-07 Abraxis Bioscience, Llc Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US20030199425A1 (en) * 1997-06-27 2003-10-23 Desai Neil P. Compositions and methods for treatment of hyperplasia
IL149360A0 (en) * 1999-10-27 2002-11-10 Baker Norton Pharma Method and compositions for administering taxanes orally to human patients
US8067032B2 (en) 2000-12-22 2011-11-29 Baxter International Inc. Method for preparing submicron particles of antineoplastic agents
US9700866B2 (en) 2000-12-22 2017-07-11 Baxter International Inc. Surfactant systems for delivery of organic compounds
US20060003012A9 (en) 2001-09-26 2006-01-05 Sean Brynjelsen Preparation of submicron solid particle suspensions by sonication of multiphase systems
IL160570A0 (en) 2001-09-26 2004-07-25 Baxter Int Preparation of submicron sized nanoparticles via dispersion and solvent or liquid phase removal
AU2002362836B2 (en) 2001-10-15 2008-05-22 Crititech, Inc. Compositions and methods for delivery of poorly water soluble drugs and methods of treatment
ITMI20020680A1 (en) * 2002-03-29 2003-09-29 Acs Dobfar Spa IMPROVED ANTI-TUMOR COMPOSITION BASED ON PACLITAXEL AND METHOD FOR ITS OBTAINING
NZ518997A (en) * 2002-05-16 2004-12-24 Interag Injection formulation for parenteral administration of biodegradable implant for sustained release of active agent
SI21222A (en) * 2002-05-28 2003-12-31 Krka, Tovarna Zdravil, D.D., Novo Mesto Method for preparation of nanoparticles
GB0216700D0 (en) 2002-07-18 2002-08-28 Astrazeneca Ab Process
KR20200083657A (en) 2002-12-09 2020-07-08 아브락시스 바이오사이언스, 엘엘씨 Compositions and methods of delivery of pharmacological agents
GB0302673D0 (en) 2003-02-06 2003-03-12 Astrazeneca Ab Pharmaceutical formulations
IL160095A0 (en) * 2004-01-28 2004-06-20 Yissum Res Dev Co Formulations for poorly soluble drugs
JPWO2006073154A1 (en) * 2005-01-07 2008-06-12 エーザイ・アール・アンド・ディー・マネジメント株式会社 Pharmaceutical composition and method for producing the same
US8735394B2 (en) 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
DK1853250T3 (en) 2005-02-18 2012-01-23 Abraxis Bioscience Llc Combinations and ways of administering therapeutic agents and combination therapy
BRPI0612071A2 (en) * 2005-06-14 2010-10-19 Baxter Int pharmaceutical formulations to minimize drug interactions
BRPI0615265A8 (en) * 2005-08-31 2018-03-06 Abraxis Bioscience Llc compositions comprising low water soluble pharmaceutical agents and antimicrobial agents
RS20080167A (en) * 2005-10-21 2009-07-15 Panacea Biotec Limited, Novel improved compositions for cancer therapy
US8980323B2 (en) 2006-08-29 2015-03-17 Fujifilm Corporation Hydrophilic matrix containing poorly water-soluble compound and method for producing the same
CN101605535A (en) 2006-12-14 2009-12-16 阿布拉科斯生物科学有限公司 Treat breast carcinoma with the nano-particle that comprises taxane based on hormone receptor status
HUE039497T2 (en) 2007-03-07 2019-01-28 Abraxis Bioscience Llc Nanoparticle comprising rapamycin and albumin as anticancer agent
EP2155188B1 (en) 2007-06-01 2013-10-09 Abraxis BioScience, LLC Methods and compositions for treating recurrent cancer
FR2924024B1 (en) 2007-11-27 2012-08-17 Centre Nat Rech Scient NANOPARTICLES OF THERAPEUTIC ACTIVE INGREDIENTS OF LOW AQUEOUS SOLUBILITY
KR20100048751A (en) * 2008-10-31 2010-05-11 주식회사 동성바이오레인 Capsulated functional dual core aerosol composition and the method for their manufacture
WO2010060811A2 (en) * 2008-11-27 2010-06-03 Basf Se Surface active proteins as excipients in solid pharmaceutical formulations
US9493545B2 (en) 2009-02-11 2016-11-15 Albumedix A/S Albumin variants and conjugates
SMT201900751T1 (en) 2009-04-15 2020-03-13 Abraxis Bioscience Llc Prion-free nanoparticle compositions and methods
EP3421491A3 (en) 2009-10-30 2019-03-27 Albumedix Ltd Albumin variants
EP2552438B1 (en) 2010-03-26 2016-05-11 Abraxis BioScience, LLC Methods of treatment of hepatocellular carcinoma
CA3087813A1 (en) 2010-03-29 2011-10-06 Abraxis Bioscience, Llc Methods of treating cancer
AU2011232862B2 (en) 2010-03-29 2016-03-03 Abraxis Bioscience, Llc Methods of enhancing drug delivery and effectiveness of therapeutic agents
CN106924219A (en) 2010-06-04 2017-07-07 阿布拉科斯生物科学有限公司 The method for treating cancer of pancreas
CA2858593C (en) 2011-12-14 2022-05-17 Abraxis Bioscience, Llc Use of polymeric excipients for lyophilization or freezing of particles
JP6441682B2 (en) 2012-03-16 2018-12-19 アルブミディクス リミティド Albumin variant
JP6487328B2 (en) 2012-11-08 2019-03-20 アルブミディクス リミティド Albumin variant
US9149455B2 (en) 2012-11-09 2015-10-06 Abraxis Bioscience, Llc Methods of treating melanoma
PT106738B (en) * 2013-01-09 2015-06-08 Hovione Farmaciencia Sa METHOD FOR THE CONTROL OF OSTWALD DIFUSIONAL DEGRADATION PHENOMENON (OSTWALD RIPENING) IN THE PROCESSING OF PARTICLES OF A PHARMACEUTICAL INGREDIENT
US9511046B2 (en) 2013-01-11 2016-12-06 Abraxis Bioscience, Llc Methods of treating pancreatic cancer
KR20150118123A (en) 2013-02-16 2015-10-21 노보자임스 바이오파마 디케이 에이/에스 Pharmacokinetic animal model
EP2968254B1 (en) 2013-03-12 2020-04-22 Abraxis BioScience, LLC Methods of treating lung cancer
CA2903548A1 (en) 2013-03-14 2014-09-25 Abraxis Bioscience, Llc Methods of treating bladder cancer
CN104548116A (en) * 2013-10-11 2015-04-29 程树海 Preparation method of stable protein drug-loaded microparticle system
CN104434808A (en) 2014-07-03 2015-03-25 石药集团中奇制药技术（石家庄）有限公司 Therapeutic nanoparticles and preparation method thereof
US10527604B1 (en) 2015-03-05 2020-01-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel
US10705070B1 (en) 2015-03-05 2020-07-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug
JP6987644B2 (en) 2015-06-29 2022-01-05 アブラクシス バイオサイエンス， エルエルシー How to treat epithelioid cell tumors
CN108137674B (en) 2015-08-20 2022-12-06 阿尔布梅迪克斯医疗有限公司 Albumin variants and conjugates
WO2018082758A1 (en) 2016-11-04 2018-05-11 Aarhus Universitet Identification and treatment of tumors characterized by an overexpression of the neonatal fc receptor
DE102016125666A1 (en) * 2016-12-23 2018-06-28 Michael Denck HSA Galenik
CN110753541A (en) * 2017-04-24 2020-02-04 Zy治疗公司 Pharmaceutical compositions for in vivo delivery, process for preparing substantially water insoluble pharmacologically active agents
KR20200135410A (en) 2018-03-20 2020-12-02 아브락시스 바이오사이언스, 엘엘씨 Methods of treating central nervous system disorders through administration of mTOR inhibitors and albumin nanoparticles
US11497737B2 (en) 2019-10-28 2022-11-15 Abraxis Bioscience, Llc Pharmaceutical compositions of albumin and rapamycin
CN114786654A (en) * 2019-12-11 2022-07-22 密执安大学评议会 Compositions and methods for systemic delivery of Bcl-2 and Bcl-xL antagonists

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4671954A (en) * 1983-12-13 1987-06-09 University Of Florida Microspheres for incorporation of therapeutic substances and methods of preparation thereof
US5916596A (en) * 1993-02-22 1999-06-29 Vivorx Pharmaceuticals, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US5439686A (en) * 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
ES2435944T3 (en) * 1997-06-27 2013-12-26 Abraxis Bioscience, Llc New formulations of pharmacological agents, methods for their preparation and methods for their use

Also Published As

Publication number Publication date
AU5035900A (en) 2000-12-12
WO2000071079A2 (en) 2000-11-30
EP1178786A4 (en) 2006-03-01
CA2684454A1 (en) 2000-11-18
EP1178786A1 (en) 2002-02-13
AU784416B2 (en) 2006-03-30
AU2006202836B2 (en) 2009-10-08
AU2006202836A1 (en) 2006-07-27
CA2371912C (en) 2010-02-16
AU2009217409A1 (en) 2009-10-08
CA2371912A1 (en) 2000-11-30
WO2000071079A3 (en) 2008-03-27

Similar Documents

Publication Publication Date Title
EP1178786A4 (en) Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
HK1050367A1 (en) Pharmaceutically active compounds.
IL137346A0 (en) Pharmaceutically active morpholinol
HK1048999A1 (en) Azepinoindole derivatives, their preparation and use thereof
HUP0402113A3 (en) 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity, preparation and use thereof
ZA200201509B (en) Pharmaceutically active sulfonamide derivatives.
IL150022A0 (en) Imidazo [1,3,5] triazinones and the use thereof
HK1040398A1 (en) Pyridopyranoazepine derivatives, preparation and therapeutic use
HUP0105039A3 (en) Fungicidal propargylether derivatives, preparation and use thereof
ZA200007415B (en) Amino acid derivatives and drugs containing the same as the active ingredient.
HK1031725A1 (en) 3-amino-3-arylpropan-1-ol-derivates, their preparation and their use
HRP20040171A2 (en) Combined preparations, containing 1,4-benzothiepine-1,1-dioxide derivatives and other active substances, and the use thereof
AU2662799A (en) Modified pharmacologically active agents and improved therapeutic methods employing same
HUP0202377A2 (en) N-substituted perhydrodiazines, preparation and use thereof
ZA200110046B (en) Therapeutic agents.
EP1234834A4 (en) 1,3,4-oxadiazolin-2-one derivatives and drugs containing these derivatives as the active ingredient
SI1043306T1 (en) 3-amino-3-arylpropan-1-ol-derivates, their preparation and use
AU2001262699A1 (en) Biologically active agents and drugs
ZA989312B (en) Novel pharmaceutically active compounds, their preparation and use.
HUP0203678A3 (en) Nitro-sulfobenzamide-derivatives, preparation and use thereof
HUP0203455A3 (en) 2-arylquinoline derivatives, preparation and therautic use thereof
IL150237A0 (en) Benzophenone glycopyranosides, preparation and therapeutic use
AUPP899699A0 (en) Peptides, agents and methods
GB9801230D0 (en) Pharmaceutically active morpholinol
IL158978A0 (en) Pharmaceutically active morpholinol